Abstract:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis in different types of cancer cells via activation of caspase cascade. TRAIL interacts with its cognate receptors that placed on cancer cells surface, including TRAIL-R1 (death receptor 4, DR4), TRAIL-R2 (death receptor 5, DR5), TRAIL-R3 (decoy receptor 1, DcR1), TRAIL-R4 (decoy receptor 2, DcR2), and osteoprotegerin (OPG). Despite high apoptosis-inducing ability of TRAIL, various cancerous cells gain resistance to TRAIL gradually, and consequently TRAIL potential for apoptosis stimulation in these cells diminishes intensely. According to diverse ranges of examinations, intracellular anti-apoptotic proteins, such as cellular-FLICE inhibitory protein (c-FLIP), apoptosis inhibitors (IAPs), myeloid cell leukemia sequence 1 (MCL-1), BCL-2, BCL-XL, and survivin play key role in cancer cells resistance to TRAIL. These proteins attenuate cancer cells sensitivity to TRAIL via various functions, importantly through caspase cascade suppression. The c-FLIP avoids from caspase 8 activation by FADD via binding to caspase 8 cleavage of FADD. Moreover, it activates signaling pathways that involved in cancer cells survival and proliferation. Intriguingly, it appears that the down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP is effectiveness goal for TRAIL-resistant cancers therapy, because their up-regulation in association with poor prognosis has been observed in various types of TRAIL-resistant cancers. In this review, we tried to collect and examine investigations that researchers have been able to sensitize cancer cells to TRAIL through targeting of c-FLIP alone or with other intracellular anti-apoptotic proteins directly or indirectly. It seems that co-treatment of resistant cells by TRAIL with other therapeutic agents with the aim of intracellular anti-apoptotic proteins inhibition is hopeful and attractive approach to overcome various TRAIL-resistant cancers.

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

TNF-related Apoptosis-Inducing Ligand and Tumor

Influence of inhibitor of signal transduction on the cell apoptosis induced by TNF β

Membrane-bound Ligand-Dependent Bystander Effect of the TNF-related Apoptosis-Inducing Ligand (TRAIL)

TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

Molecular Mechanisms of TRAIL-induced Apoptosis of Cancer Cells

Developing TRAIL/TRAIL death receptor-based cancer therapies

Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors Signal NF-κB and JNK Activation and Apoptosis Through Distinct Pathways

Inducible Resistance Of Tumor Cells To Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2-Mediated Apoptosis By Generation Of A Blockade At The Death Domain Function

TRAIL-induced apoptosis proceeding from caspase-3-dependent and -independent pathways in distinct HeLa cells.

Advance Research in Apoptosis Mediating by Death Receptor

Mechanism of TRAIL Induced Tumor Cell Apoptosis and Application of TRAIL Based on Tumor Therapy

Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Glioma U87 Cells

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induces Glioma U87 Cell Apoptosis Through the Mitochondrial Apoptotic Pathway

Relationship Between Tumor Tolerance to TRAIL and Its Receptors

Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL